Kyverna surges after IPO, and CEO lays out plans for cell therapy in immune diseases

Kyverna Therapeutics started its first day as a public biotech on a strong note, with its shares $KYTX rising more than 50% Thursday afternoon after pricing at $22 and raising $319 million for the company.

But don’t call the Nasdaq IPO an…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks